Visible Particulates for Injectable Drugs

Why visible particulates are important?

Regulatory agencies worldwide explicitly require the use of visible particulates.

USP 1790

7.5 These qualified defects standard units are then assembled into test sets, which may be used to specifically challenge the particle detection technique of human inspectors, used as part of a defect test set (including container-closure defects) for human qualification or for comparison during automated equipment qualification and validation. When possible, the test set should be prepared with duplicate product units per particle type and size to ensure that backup units are available in the event that a standard container is broken or the particle is trapped or lost within the container.

EU GMP

8.30 A defect library should be generated and maintained which captures all known classes of defects. The defect library should be used for the training of production and quality assurance personnel. Critical defects should not be identified during any subsequent sampling and inspection of acceptable containers.

8.31 The qualification should be undertaken using appropriate samples from the manufacturer's defect library sets.

8.32 Where automated methods of inspection are used, the process should be validated to detect known defects (which may impact product quality or safety) and be equal to, or better than, manual inspection methods. The performance of the equipment should be challenged using representative defects prior to start up and at regular intervals throughout the batch.

Chinese Pharmacopoeia 2025

Visible particulates are defined as insoluble matter that can be observed by the unaided eye under specified conditions, with particle size or length typically greater than 50 μm.

Two primary methods are available for the inspection of visible particulates: the visual inspection  method and the light scattering method. The visual inspection method is generally the most commonly used approach. For products for which the visual inspection method is not suitable—such as those packaged in dark transparent containers or those with deeply colored liquids (generally darker than Standard Color Solution No. 7)—the light scattering method may be employed as an alternative.

Chinese GMP Guidelines 2023

Manufacturers shall use risk assessment tools to identify potential defect types for the product, taking into account product characteristics, manufacturing processes, primary packaging materials, and historical defect data. Defect types shall be classified into severity levels-typically critical, major, and minor-based primarily on the impact on patient safety. Probability of Detection (PoD) criteria shall be rationally established for each defect type.

Defect samples shall be prepared for use in manual inspection qualification or for comparison with alternative (automated) methods. To ensure that the prepared defective samples are representative, they may be obtained from the following two sources:

1. Defect samples collected from actual manufacturing processes shall be visually inspected by multiple qualified light inspection personnel, with each unit inspected 30 to 50 times in total. The detection rate (Probability of Detection) shall be calculated, and defect samples shall be classified based on the resulting detection rates.
2. Defects shall be prepared in the laboratory using materials that correspond to potential contamination sources, with defect sizes that are quantifiable.